Medscape is available in 5 Language Editions – Choose your Edition here.


Actinic Keratosis Treatment & Management

  • Author: James M Spencer, MD; Chief Editor: William D James, MD  more...
Updated: Apr 07, 2016

Medical Care

Actinic keratoses may remain unchanged, spontaneously resolve, or progress to invasive squamous cell carcinoma.[1] The fate of any one actinic keratosis is impossible to predict. Although the risk of progression of any one actinic keratosis to invasive squamous cell carcinoma is small (at most approximately 10%),[18] a patient may have many lesions, and thus the risk of progression becomes significant. Additionally, actinic keratoses can be clinically indistinguishable from more serious cutaneous malignancies, including squamous cell carcinoma and lentigo maligna.[40, 41] Therapy is generally well tolerated and simple; therefore, treatment of all actinic keratoses is warranted.

The appropriate treatment is generally chosen based on the number of lesions present and the efficacy of the treatment.[42] Additional variables to consider include persistence of the lesion(s), age of the patient, history of skin cancer, and tolerability of the treatment modality.[18] Treatment consists of 2 broad categories: surgical destruction of the lesion and medical therapy. Medical management begins with educating the patient to limit sun exposure. Patients should be cautioned to avoid sun exposure from 10:00 am to 3:00 pm as much as possible. They also must wear adequate sunscreens and protective clothing daily.[43]

Medical therapy has the advantage of being able to treat large areas with many lesions. The disadvantages of medical therapies include lengthy courses of treatment with irritation and discomfort. The US Food and Drug Administration (FDA) has approved five medications for the treatment of actinic keratoses. These are topical 5-fluorouracil (5-FU), 5% and 3.75% imiquimod cream, topical diclofenac gel, ingenol mebutate, and PDT with topical delta-aminolevulinic acid.[11, 12, 13]


The most experience in topical therapy for actinic keratoses is with 5-FU, known to inhibit thymidylate synthetase and cause cell death in actively proliferating cells.[44] Several formulations are available, including a 5% cream or solution, a 2% solution, a 1% cream or solution, and, most recently, a micronized 0.5% cream.[11] Although not well studied, efficacy among the various formulations does not seem to differ significantly.[45, 46]

The most popular formulation is the 5% cream, which is applied twice daily for 1 month. During the treatment phase, the lesions become increasingly erythematous and cause discomfort; small subclinical lesions become visible. This treatment can be temporarily disfiguring, with erythematous ulcerations and crust formation. However, if the patient completes the treatment, the lesions usually heal within 2 weeks of stopping treatment, the complexion is smooth, and the actinic keratoses are improved.

The 0.5% micronized cream was developed to increase tolerability because inflammation and discomfort can be a limiting factor in the use of topical 5-FU. The 0.5% micronized cream is applied once daily for 1 month.

Usage of the 0.5% micronized cream 1 week prior to cryosurgery has also been shown to produce complete lesion clearance in a higher number of patients compared with cryosurgery alone (32.4% and 15%, respectively).[47] Note the images below.

Actinic keratosis during treatment with topical 5- Actinic keratosis during treatment with topical 5-fluorouracil. Courtesy of Hon Pak, MD.
Actinic keratosis right after treatment with topic Actinic keratosis right after treatment with topical 5-fluorouracil. Courtesy of Hon Pak, MD.


Imiquimod is a topical medication that up-regulates a variety of cytokines, which, in turn, invoke a nonspecific immune response (interferons, natural killer cells) and a specific immune response (T cells). It is applied 2-3 times a week for up to 4 months, although generally 1 month is sufficient.[48] Reaction to the drug is idiosyncratic, with some patients barely reacting and others developing marked inflammation. Subclinical lesions previously not appreciated may become inflamed during therapy. In patients with a brisk inflammatory response, dosing is reduced to twice or even once a week, with preservation of therapeutic efficacy but increased tolerability.

Two new formulations of imiquimod (2.5% and 3.75%) were studied and found to be efficacious in clearing actinic keratoses (25% and 34% clearance, respectively), with a more intuitive daily dosing schedule. Although not as efficacious as 5% imiquimod, the new formulations cause less irritation, promoting better compliance.[49] Experimental evidence suggests patients may develop T-cell memory after treatment with this drug and thus may be less likely to develop new actinic keratoses in the future. Imiquimod 5% cream has also been shown to be safe and effective in transplantation patients.[50, 51]

Ingenol mebutate topical

Ingenol mebutate gel (Picato) was approved by the FDA for actinic keratosis in January 2012 as a 2-3 day course of therapy. The dosage for actinic keratosis differs depending on the application site. The 0.015% gel is used for application to the face or scalp for 3 consecutive days, whereas the 0.05% gel is used for application to the trunk or extremities for 2 consecutive days.

Four multicenter, randomized, double-blind studies showed that ingenol mebutate gel applied topically for 2-3 days is effective for field treatment of actinic keratoses. The studies reported adverse effects that were generally mild to moderate in intensity and resolved without sequelae.[52] A phase III randomized, double-blind study displayed long-term benefit of ingenol mebutate 0.015% gel for both initial and follow-up therapy.[53] A posthoc analysis of patient-reported outcomes from phase III trials using ingenol mebutate gel for actinic keratosis found that treatment with this gel improved patients’ quality of life and treatment satisfaction, owing to higher degrees of lesion clearance.[54]

Although a precise mechanism of action has not been defined, a dual mechanism of action was described by Rosen et al. This dual mechanism includes (1) rapid lesion necrosis by mitochondrial swelling and membrane disruption and (2) specific neutrophil-mediated, antibody-dependent cellular cytotoxicity by antibodies produced from B cells that bind to antigens on dysplastic epidermal cells.[55]

Follow-up study supports these findings.[56, 57]

Jim On et al investigated the hypothesis that ingenol mebutate gel targets cell death in proliferating keratinocytes versus healthy skin by studying the local skin reaction (LSR) score after two cycles of treatment. The study included 20 participants with actinic keratoses on their face and scalp who applied 0.015% gel once daily for 3 days in two sequential 4-week cycles. The study found that the composite LSR score was significantly lower during the second cycle, thus suggesting that ingenol mebutate gel provides targeted therapy of actinic keratoses over cumulative dosing.[58]

Topical diclofenac sodium 3% gel

Topical diclofenac sodium 3% gel is a nonsteroidal anti-inflammatory drug approved by the FDA for the treatment of actinic keratosis. Its mechanism of action against actinic keratoses is unknown. It is effective therapy when applied twice a day for 3 months. A shorter course of therapy is dramatically less effective. Its chief advantage is that it produces little-to-no inflammation and thus is very well tolerated. Diclofenac therapy after cryosurgery has also been shown to produce complete lesion clearance in a higher number of patients compared with cryosurgery alone (64% vs 32%, respectively).[59]

Photodynamic therapy

PDT uses a light-sensitizing compound that preferentially accumulates in actinic keratosis cells, where it can be activated by the appropriate wavelength of light. Delta-aminolevulinic acid is a component of the heme biosynthetic pathway that accumulates preferentially in dysplastic cells. Once inside these cells, it is enzymatically converted to protoporphyrin IX, a potent photosensitizer. With exposure to light of an appropriate wavelength, oxygen free radicals are generated and cell death results.[14]

Patients experience pain, similar in scope to the pain resulting from topical 5-FU, in the areas treated. The treated lesions may become erythematous and crusted. One treatment with PDT appears to be as effective as topical 5-FU therapy.[60]

A recent meta-analysis and systematic review assessed the effectiveness of PDT versus cryotherapy and found that PDT had a 14% better chance of complete lesion clearance at 3 months for thin actinic keratoses on the face and scalp compared with cryotherapy.[61]

Immunosuppressed patients may also benefit from PDT in the prevention of nonmelanoma skin cancers.[62]

When used with light sources that have a cosmetic benefit by themselves, such as the pulsed dye laser or intense pulsed light devices, a cosmetic benefit may be seen from the use of topical PDT beyond that of actinic keratosis eradication. Compared with other destructive therapeutic options such as cryotherapy, PDT may offer better cosmetic results and higher patient preference.[62, 63]

An unknown parameter in the use of topical PDT is the optimal incubation time following application of the topical aminolevulinic acid before light exposure. A second unknown parameter is the optimal light source to use for this treatment. Ongoing studies are addressing these issues.[62, 64]

Another photosensitizing agent approved in the use of PDT is methyl-5-aminolaevulinate (MAL). Comparison studies between ALA and MAL are not currently decisive. A study investigating the clinical efficacy of ALA- versus MAL-PDT in the treatment of actinic keratosis, Bowen disease, nodular basal cell carcinoma, and superficial basal cell carcinoma found that there were no statistically significant differences in their treatment outcomes using either of these agents.[65] However, a randomized, multicenter, observer-blind, placebo-controlled trial comparing the efficacy of BF-200 ALA versus MAL cream in the treatment of actinic keratoses lesions demonstrated that PDT with BF-200 ALA was superior to the MAL cream regarding patient complete clearance of lesions. Six- and 12-month follow-up studies substantiated the efficacy of PDT with BF-200 ALA and the lower recurrence rates of lesions with BF-200 ALA treatment versus MAL treatment.[66, 67] Looking beyond lesion clearance, MAL -PDT was found to be less painful when compared with ALA-PDT in a retrospective monocentric study of 173 patients.[68]


Surgical Care

The goal of surgical therapy is complete eradication of the actinic keratoses, usually by physical destruction, with limited-to-no damage to surrounding healthy tissue. When the diagnosis is unclear and an invasive tumor is possible, biopsy is indicated. However, biopsy generally leaves a scar.

Cryosurgery refers to use of a cryogen to lower the temperature of the skin and produce cell death. The most common cryogen used is liquid nitrogen, with a temperature of -195.8°C. Keratinocytes die when exposed to approximately -40 to -50°C. Other structures in the skin, such as collagen, blood vessels, and nerves, are more resistant to the lethal effects of cold than keratinocytes. Melanocytes are more sensitive than keratinocytes; thus, cryosurgery often leaves white spots. This technique has not been studied in a scientific fashion until 2004, when it was demonstrated to produce an overall clearance rate of 67-88%.[63, 69]

Lesions suggestive of invasive cancer may be treated with curettage, shave excision, or conventional excision, all of which provide a sample for histologic evaluation. These treatments require local anesthesia, produce a wound that requires time to heal, and are likely to scar.

Cosmetic resurfacing procedures, in which the entire epidermis is removed, sometimes with some portion of the dermis, are effective for actinic keratosis eradication. Cosmetic resurfacing procedures include medium and deep chemical peels, dermabrasion, and ablative laser resurfacing.[15, 16, 17] All of these are cosmetic procedures unlikely to be covered by insurance, all carry the risk of scarring and infection, and all require experience and expertise on the part of the dermatologic surgeon. They are highly unlikely to be performed solely for actinic keratosis therapy.



One study has suggested that a low-fat diet in humans leads to greater resolution of existent actinic keratoses and the development of fewer new ones during the study period.[30]



Instruct patients to practice sun safety, such as the use of sunscreen and protective clothing, and to limit outdoor activity from 10:00 am to 3:00 pm.[43]



Lesions may progress into invasive squamous cell carcinomas. A biopsy should be performed on nodular, indurated, or unresponsive lesions.[9]



The development of these lesions is directly proportional to sun exposure. Actinic keratoses can be reduced or delayed by using sunscreens and reducing sun exposure.[43] Patients should limit recreational exposure, and those who work outdoors should consider making adjustments in their work-related sun exposure. For patients forced to undergo sun exposure, recommend applying a sunscreen of sun protection factor (SPF) 30 or more and wearing protective clothing daily.[43]


Long-Term Monitoring

If the lesions do not respond to topical therapy, they can be treated with cryotherapy with liquid nitrogen spray for 5-20 seconds.[69] Lesions become irritated and ulcerate, and eventually the diseased pathology is sloughed from healthy skin.[69]

A biopsy of more advanced lesions that are indurated should be performed to rule out an invasive carcinoma.[9]

Contributor Information and Disclosures

James M Spencer, MD Professor of Clinical Dermatology, Mount Sinai School of Medicine; Private Practice, Spencer Dermatology

James M Spencer, MD is a member of the following medical societies: American Academy of Cosmetic Surgery, American Academy of Dermatology, American College of Mohs Surgery, American Medical Association, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, International Society for Dermatologic Surgery

Disclosure: Received grant/research funds from Genentech for independent contractor; Received grant/research funds from DUSA for independent contractor; Received honoraria from Leo Pharmicuticals for review panel membership.


Laura Jordan, DO, MA, MS, MLS Dermatology-Focus Traditional Rotating Intern, UH Regional Hospitals

Laura Jordan, DO, MA, MS, MLS is a member of the following medical societies: American Osteopathic College of Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael J Wells, MD, FAAD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Kelly M Cordoro, MD Assistant Professor of Clinical Dermatology and Pediatrics, Department of Dermatology, University of California, San Francisco School of Medicine

Kelly M Cordoro, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Medical Society of Virginia, Society for Pediatric Dermatology, Women's Dermatologic Society, Association of Professors of Dermatology, National Psoriasis Foundation, Dermatology Foundation

Disclosure: Nothing to disclose.

Michelle Henry, MD Fellow in Procedural Dermatology, Department of Dermatology, Lahey Clinic, Harvard Medical School

Disclosure: Nothing to disclose.


Amy Lynn Basile, DO, MPH Sun Coast Hospital/Largo Medical Center, Largo, Florida

Disclosure: Nothing to disclose.

Mary Farley, MD Dermatologic Surgeon/Mohs Surgeon, Anne Arundel Surgery Center

Disclosure: Nothing to disclose.

James Fulton Jr, MD, PhD Medical Director, Fulton Skin Institute

Disclosure: Nothing to disclose.

  1. Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis - an update. Br J Dermatol. 2007 Dec. 157 Suppl 2:18-20. [Medline].

  2. Schwartz RA. Premalignant keratinocytic neoplasms. J Am Acad Dermatol. 1996 Aug. 35(2 Pt 1):223-42. [Medline].

  3. Schwartz RA, Bridges TM, Butani AK, Ehrlich A. Actinic keratosis: an occupational and environmental disorder. J Eur Acad Dermatol Venereol. 2008 May. 22(5):606-15. [Medline].

  4. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol. 1998 Dec. 139(6):1033-9. [Medline].

  5. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):4-7. [Medline].

  6. Franceschi S, Levi F, Randimbison L, La Vecchia C. Site distribution of different types of skin cancer: new aetiological clues. Int J Cancer. 1996 Jul 3. 67(1):24-8. [Medline].

  7. James C, Crawford R, Martika M. Actinic Keratosis. James C, Crawford R, Martika M, Marks R, eds. WHO Pathology and Genetics, Skin Tumors. Lyon: IARC Press; 2006. 30-33.

  8. Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol. 2002 May. 146(5):810-5. [Medline].

  9. Marks VJ. Actinic keratosis. A premalignant skin lesion. Otolaryngol Clin North Am. 1993 Feb. 26(1):23-35. [Medline].

  10. Sanmartin O, Guillen C. Images in clinical medicine. Fluorescence diagnosis of subclinical actinic keratoses. N Engl J Med. 2008 May 8. 358(19):e21. [Medline].

  11. Spencer JM, Hazan C, Hsiung SH, Robins P. Therapeutic decision making in the therapy of actinic keratoses. J Drugs Dermatol. 2005 May-Jun. 4(3):296-301. [Medline].

  12. Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J. Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod. Cutis. 2003 May. 71(5):365-70. [Medline].

  13. Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J. Topical therapy for actinic keratoses, II: Diclofenac, colchicine, and retinoids. Cutis. 2003 May. 71(5):373-9. [Medline].

  14. Fuchs J, Thiele J. The role of oxygen in cutaneous photodynamic therapy. Free Radic Biol Med. 1998 Mar 15. 24(5):835-47. [Medline].

  15. Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2006 Aug. 142(8):976-82. [Medline].

  16. Sherry SD, Miles BA, Finn RA. Long-term efficacy of carbon dioxide laser resurfacing for facial actinic keratosis. J Oral Maxillofac Surg. 2007 Jun. 65(6):1135-9. [Medline].

  17. Winton GB, Salasche SJ. Dermabrasion of the scalp as a treatment for actinic damage. J Am Acad Dermatol. 1986 Apr. 14(4):661-8. [Medline].

  18. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):23-4. [Medline].

  19. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):18-22. [Medline].

  20. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992 Aug 21. 70(4):523-6. [Medline].

  21. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol. 1994 Oct. 131(4):455-64. [Medline].

  22. Feldman SR, Fleischer AB Jr, McConnell RC. Most common dermatologic problems identified by internists, 1990-1994. Arch Intern Med. 1998 Apr 13. 158(7):726-30. [Medline].

  23. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988 Apr 9. 1(8589):795-7. [Medline].

  24. Backvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F. Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res. 2005 Apr 1. 571(1-2):65-79. [Medline].

  25. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett. 1994 Sep 30. 85(1):23-9. [Medline].

  26. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004 May-Jun. 22(3):189-96. [Medline].

  27. Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007 Sep. 33(9):1099-101. [Medline].

  28. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):11-7. [Medline].

  29. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol. 2006 Jul. 155(1):9-22. [Medline].

  30. Black HS, Herd JA, Goldberg LH, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med. 1994 May 5. 330(18):1272-5. [Medline].

  31. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995 Jan. 32(1):95-8. [Medline].

  32. Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006 Nov. 55(5):741-60; quiz 761-4. [Medline].

  33. Cooper JZ, Brown MD. Special concern about squamous cell carcinoma of the scalp in organ transplant recipients. Arch Dermatol. 2006 Jun. 142(6):755-8. [Medline].

  34. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992 Jun. 26(6):976-90. [Medline].

  35. Parrish JA. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med. 2005 Dec 22. 353(25):2712-3. [Medline].

  36. Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer. 1990 Sep 15. 46(3):356-61. [Medline].

  37. Weissenborn SJ, Nindl I, Purdie K, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol. 2005 Jul. 125(1):93-7. [Medline].

  38. McBride P, Neale R, Pandeya N, Green A. Sun-related factors, betapapillomavirus, and actinic keratoses: a prospective study. Arch Dermatol. 2007 Jul. 143(7):862-8. [Medline].

  39. Pfister H, Fuchs PG, Majewski S, Jablonska S, Pniewska I, Malejczyk M. High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population. Arch Dermatol Res. 2003 Dec. 295(7):273-9. [Medline].

  40. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000 Jan. 42(1 Pt 2):8-10. [Medline].

  41. Pock L, Drlik L, Hercogova J. Dermatoscopy of pigmented actinic keratosis--a striking similarity to lentigo maligna. Int J Dermatol. 2007 Apr. 46(4):414-6. [Medline].

  42. Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol. 2008 Jan. 7(1):23-5. [Medline].

  43. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993 Oct 14. 329(16):1147-51. [Medline].

  44. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol. 1970 Feb. 101(2):132-9. [Medline].

  45. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005 Oct. 9(5):209-14. [Medline].

  46. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002 Jun. 24(6):990-1000. [Medline].

  47. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol. 2006 Feb. 5(2):133-9. [Medline].

  48. Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007 Dec. 157 Suppl 2:41-6. [Medline].

  49. Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010 Apr. 62(4):573-81. [Medline].

  50. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007 Dec. 157 Suppl 2:25-31. [Medline].

  51. Ulrich C, Busch JO, Meyer T, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol. 2006 Aug. 155(2):451-4. [Medline].

  52. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012 Mar 15. 366(11):1010-9. [Medline].

  53. Garbe C, Basset-Seguin N, Poulin Y, et al. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study. Br J Dermatol. 2016 Mar. Vol 174(3):505-13. [Medline].

  54. Augustin M, Tu JH, Knudsen KM, Erntoft S, Larsson T, Hanke CW. Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes. J Am Acad Dermatol. 2015 May. Vol 72(5):816-21. [Medline].

  55. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2011 Nov 4. [Medline].

  56. Boggs W. Ingenol Mebutate Gel Effective for Actinic Keratoses. Medscape. Mar 28 2013. Available at http://Available at: Accessed: April 8, 2013.

  57. Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013 Jun. 149(6):666-70. [Medline].

  58. Jim On SC, Haddican M, Yaroshinsky A, Singer G, Lebwohl M. Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosis. Cutis. 2015 Jan. 95(1):47-51. [Medline].

  59. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008 Jul. 7(7):669-73. [Medline].

  60. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol. 1999 Sep. 41(3 Pt 1):414-8. [Medline].

  61. Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. JAMA Dermatol. 2014 Dec. 150(12):1281-8. [Medline].

  62. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007 Jan. 56(1):125-43. [Medline].

  63. Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl aminolaevulinate-photodynamic therapy vs. cryotherapy for multiple actinic keratoses on the extremities. Br J Dermatol. 2008 May. 158(5):994-9. [Medline].

  64. McLoone N, Donnelly RF, Walsh M, et al. Aminolaevulinic acid diffusion characteristics in 'in vitro' normal human skin and actinic keratosis: implications for topical photodynamic therapy. Photodermatol Photoimmunol Photomed. 2008 Aug. 24(4):183-90. [Medline].

  65. Tarstedt M, Gillstedt M, Wennberg Larkö AM, Paoli J. Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers. J Eur Acad Dermatol Venereol. 2016 Mar. Vol 30(3):420-23. [Medline].

  66. Dirschka T, Radny P, Dominicus R, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol. 2012 Jan. Vol 166(1):137-46. [Medline].

  67. Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol. 2013 Apr. Vol 168(4):825-36. [Medline].

  68. Gholam P, Weberschock T, Denk K, Enk A. Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. Dermatology. 2011. Vol 222(4):358-62. [Medline].

  69. Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004 Sep. 43(9):687-92. [Medline].

Actinic keratosis. Courtesy of Hon Pak, MD.
Actinic keratosis during treatment with topical 5-fluorouracil. Courtesy of Hon Pak, MD.
Actinic keratosis right after treatment with topical 5-fluorouracil. Courtesy of Hon Pak, MD.
Erythematous, scaly lesions on the temple area, typical of actinic keratosis.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.